Drug intelligence / Profile preview

RO5545965 + risperidone

Development stage: Phase 1
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

RO5545965 + risperidone is a combination therapy investigated for the treatment of schizophrenia. **RO5545965** is a phosphodiesterase 10A (PDE10A) inhibitor developed to modulate dopaminergic and glutamatergic signaling through inhibition of PDE10A, an enzyme highly expressed in the striatum. **Risperidone** is a second-generation antipsychotic that acts primarily as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, reducing dopaminergic and serotonergic signaling implicated in schizophrenia[1][4][2].

Targets

ADRA1A (α1A)ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)PDE10A (Phosphodiesterase 10A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on RO5545965 + risperidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5545965 + risperidone.